Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Develops Research Sector (China)

This article was originally published in PharmAsia News

Executive Summary

An increasing number of international corporations are investing in the Chinese research and development sector. A recent survey by the Organization for Economic Co-Operation and Development (OECD) shows pharmaceutical discovery is just one of the many R&D fields expanding in China. Patent applications have doubled every two years. The R&D-to-gross domestic product ratio has doubled in the last ten, from .6 percent to 1.34 percent. Major international pharmaceutical companies, including Novartis, are further fueling this trend by announcing expanded research facilities in China. According to the OECD survey, much of this expansion is leaning toward the discovery and development of new products. In the past, most China-based R&D was limited to altering already established products to suit the Chinese market. (Click here for more - May Require Paid Subscription



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts